All patients with CKD should receive the maximum tolerated dose of a renin–angiotensin–aldosterone system inhibitor (RAASi), such as an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB), and an SGLT2i, regardless of the presence of diabetes [58,80,134]. The gene discussed is REN; the disease is diabetes mellitus.